
Changing the Trajectory of Autoimmune Diseases
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on treating autoimmune diseases with high unmet medical needs. Its lead commercial product, LUPKYNIS (voclosporin), is approved for lupus nephritis. The company is advancing a pipeline including aritinercept for additional autoimmune indications.